ClinicalTrials.gg
CompletedNCT03332316Updated Nov 28, 2023

Effect of Perineural Dexamethasone on the Duration of Popliteal Nerve Block for Anesthesia After Ankle Surgery

A Phase 4 interventional study of Dexamethasone Sodium Phosphate and Ropivacaine Hydrochloride Inj 2 mg/ml in Postoperative Pain and Nerve Block, sponsored by Tampere University Hospital. Completed at 1 site in Finland. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-11-28.

Sponsored by Tampere University Hospital · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing dexamethasone phosphate in Pain, Postoperative — none open to participants now, none under way, none of them phase 3. dexamethasone phosphate · Pain, Postoperative.

Enrollment
7th of 10
84 · median 90
Started
2017
with 2 others
Phase 4
4 of 10
none open now
Registered
5th of 10
by date
Lead sponsor
2 of 10
Tampere University Hospital

Among the 10 studies testing dexamethasone phosphate in Pain, Postoperative, this one is the 7th largest by enrollment, is one of 3 that started in 2017, is one of 4 in phase 4, and was the 5th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

None of the 10 studies testing dexamethasone phosphate in Pain, Postoperative is open now. The open studies under Pain, Postoperative, anywhere →

About dexamethasone phosphate

dexamethasone phosphate: first FDA approval 1959 (DECADRON), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing dexamethasone phosphate in Pain, Postoperative as a file.
02

Study summary

Effect of perineural dexamethasone on the duration of popliteal nerve block after ankle/foot surgery

Read the detailed description

This study is proposed to explore the effect of perineural dexamethasone on the duration of popliteal nerve block for analgesia after ankle surgery.

After ankle or foot arthrodesis patients need a good analgesia. Nevertheless early mobilisation and discharge are important for the healing process after surgery. Peripheral nerve blocks have provided a safe, effective method to control early postoperative pain when symptoms are most severe. Perineural dexamethasone added to local anesthetic prolongs the duration of analgesia of the perineural nerve block.

The perineural use of dexamethasone is still off-label. There is a ongoing discussion of which has better benefits, intravenous or perineural dexamethasone.

There are multiple research where the intravenous and perineural dexamethasone use has compared, but there is still a limited amount of research of low dose perineural dexamethasone versus intravenous dexamethasone.

In this study investigators compare different doses of perineural dexamethasone added to ropivacaine 2 mg/ml 20ml. After arthrodesis under spinal anaesthesia the patients receive popliteal block ropivacaine 2 mg/ml 20 ml and dexamethasone of different doses. Groups 1 to 4 has dexamethasone doses 0, 2mg, 3mg or 4 mg.

After the popliteal nerve block investigators follow postoperative pain, opiate consumption, mobilisation and long term quality of life.

Investigators goal is to find a dexamethasone dose which is as low as possible but at the same time covers the need for a good pain relief and fast recovery postoperatively.

03

Conditions studied

  • Postoperative Pain
  • Nerve Block

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult people under ankle/foot arthrodesis as a curative therapy of ankle arthrosis or situation after ankle injury or malposition

Exclusion criteria

Exclusion Criteria:

Age under 18 years Complicated diabetes mellitus Lack of finnish language skill and/or co-operation Chronic pain medication in regular use

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
84 participants (actual)

Study arms

  • Placebo comparator
    DEXA0

    Ropivacaine Hydrochloride Inj 2mg/ml 20 ml and Sodium Chloride 9mg/mL 1 ml perineurally

    Drug: Ropivacaine Hydrochloride Inj 2 mg/ml · Drug: Sodium Chloride 9mg/mL

  • Experimental
    DEXA1

    Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,2 ml and Sodium Chloride 9mg/mL 0,8 ml perineurally

    Drug: Dexamethasone Sodium Phosphate · Drug: Ropivacaine Hydrochloride Inj 2 mg/ml · Drug: Sodium Chloride 9mg/mL

  • Experimental
    DEXA2

    Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,4 ml and Sodium Chloride 9mg/mL 0,6 ml perineurally

    Drug: Dexamethasone Sodium Phosphate · Drug: Ropivacaine Hydrochloride Inj 2 mg/ml · Drug: Sodium Chloride 9mg/mL

  • Experimental
    DEXA4

    Ropivacaine Hydrochloride Inj 2 mg/ml 20 ml and Dexamethasone Sodium Phosphate 5mg/ml 0,8 ml and Sodium Chloride 9mg/mL 0,2 ml perineurally

    Drug: Dexamethasone Sodium Phosphate · Drug: Ropivacaine Hydrochloride Inj 2 mg/ml · Drug: Sodium Chloride 9mg/mL

Interventions

  • Dexamethasone injection

    Also known as: Oradexon

  • DrugRopivacaine Hydrochloride Inj 2 mg/ml

    Ropivacaine injection

  • DrugSodium Chloride 9mg/mL

    Drug page: Sodium Chloride

    Sodium Chloride injection

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. First need of opiate

    Time after surgery when the patient needs opiate for the first time

    Time frame: 48 hours

Secondary outcomes

  1. Opiate consumption

    Total opiate consumption after surgery

    Time frame: 48 hours

  2. Pain

    Numeric rating scale NRS 0-10

    Time frame: postoperatively: at 4 hours, at 8 hours,at 12 hours, at 16 hours, at 20 hours, at 24 hours, at 28 hours, 32 hours, at 36 hours, at 40 hours, at 44 hours, at 48 hours,seventh postoperative day

  3. Mobilisation

    Toe movement every 4 hour during hospitalization

    Time frame: postoperatively: at 4 hours, at 8 hours,at 12 hours, at 16 hours, at 20 hours, at 24 hours, at 28 hours, 32 hours, at 36 hours, at 40 hours, at 44 hours, at 48 hours

  4. Blood glucose

    Blood glucose every 4 hour during hospitalization

    Time frame: postoperatively: at 4 hours, at 8 hours,at 12 hours, at 16 hours, at 20 hours, at 24 hours

Other outcomes

  1. Quality of life (EQ-5D-3L) -query

    Time frame: Before operation and 6-8 weeks, 6 months, 12 months postoperatively

  2. McGill -pain query

    Time frame: Before operation and 6-8 weeks, 6 months, 12 months postoperatively

07

Study locations

1 site
  • Tampere University Hospital
    Tampere, 33521, Finland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Nov 2023, 72 months.

Of 532 non-industry phase 4 interventional studies under Pain, Postoperative, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 32. This study's 72 months is above that.

Counting every sponsor, half of 542 studies reached it within 16 months; a quarter within 8 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2017
First posted
Nov 6, 2017
StartActual
Nov 2, 2017
Primary completionActual
Nov 21, 2023
CompletionActual
Nov 21, 2023
Last update
Nov 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03332316
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Nov 2, 2017
Primary completion
Nov 21, 2023
Completion
Nov 21, 2023
Last update
Nov 28, 2023

Study contacts

Maija-Liisa Kalliomäki, PhD
study director · Tampere University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone phosphate

Start the discussion